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ABSTRACT 
 Acute Kidney Injury (AKI) is a prevalent systemic disorder that has an extremely 
high rate of mortality even after detection. Historically, the diagnosis and treatment of 
AKI was marred by the lack of universally accepted criteria defining AKI. Therefore, 
reports of incidence and mortality varied widely depending on location and the criteria 
used at the time, but all reports indicated a poor prognosis for the patient. Until recently, 
the only modes of detecting AKI were primarily through measurements of three clinical 
findings: serum creatinine concentration, blood urea nitrogen concentration, and urine 
output. While these measurements are still widely used as standard practice, they have 
limitations in their utility because their values can fluctuate depending on a person’s age, 
gender, race, diet, and other comorbid conditions. Nevertheless, as these were the only 
universally accepted units of measurement for kidney function, the Acute Dialysis 
Quality Initiative (ADQI) used them to create the Risk, Injury, Failure, Loss, and End 
stage kidney disease (RIFLE) criteria to classify the severity of kidney injury across 
clinical settings. Eventually, modifications were made by the Acute Kidney Injury 
Network (AKIN) to increase the sensitivity of AKI diagnosis. It was not until the last 
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decade that new biomarkers of kidney injury began to be researched that provided earlier 
detection of physical kidney injury before functional manifestations would present 
themselves. Some of these new biomarkers include cystatin C, kidney injury molecule-1 
(KIM-1), and neutrophil gelatinase associated lipocalin (NGAL). This study will 
investigate how the properties of these new biomarkers are superior when compared to 
those of serum creatinine in early detection of AKI and specification as to the local site of 
injury within the nephron. The conclusion is that cystatin C has the potential to indicate 
damage to glomerular filtration while KIM-1 and NGAL have the ability to indicate 
damage to the proximal tubule. Along with the ability to provide information as to the 
specific site of renal injury, the levels of cystatin C, KIM-1, and NGAL increase much 
more rapidly and to a much higher value than serum creatinine once physical renal 
damage has occurred. These characteristics along with future research will allow for 
earlier detection of AKI, more personalized treatment plans, and an overall better 
prognosis for the patient. 
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INTRODUCTION 
 The incidence of mortality increases with the decline of kidney function because 
the kidneys are the functional organ responsible for maintaining many different 
homeostatic conditions (Murugan & Kellum, 2011). This fact along with the prevalence 
of hospital-acquired acute kidney injury (HA-AKI) in hospitalized patients makes early 
detection and proper treatment to prevent the progression of this disease a high priority. It 
has been estimated in the past that 5-25% of hospitalized patients will acquire HA-AKI 
(Pruchnicki & Dasta, 2002). With nearly 50% of cases proving to be fatal, early detection 
is critical to the treatment of HA-AKI because early renal failure often times has no 
clinical manifestations (Nally, 2002).  
 Acute kidney injury (AKI) is characterized by a decreased urinary excretion of 
nitrogenous wastes, usually in the form of urea nitrogen and creatinine, resulting from a 
sudden loss of renal function (Nolan & Anderson, 1998). AKI is further subcategorized 
into prerenal, postrenal, and intrinsic subtypes. This distinction is important because the 
initial evaluation and treatment management differ depending on the origin of the renal 
insult (Nally, 2002). Intrinsic AKI, at a frequency of 66-80%, and prerenal AKI, at a 
frequency of 12-25%, are the most common types of HA-AKI (Pruchnicki & Dasta, 
2002). While many different diseases affecting renal parenchymal cells can lead to 
intrinsic AKI, the most common etiology is acute tubular necrosis (ATN) (Palevsky, 
2012). ATN usually develops as a result of hypotension, renal ischemia, sepsis, or 
nephrotoxin exposure (Palevsky, 2012).  
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 In order to properly diagnose AKI, a standardized set of criteria was determined 
to measure glomerular function as a result of changes in urine output and serum 
creatinine level, and together they formed the Risk, Injury, Failure, Loss, and End-stage 
renal disease (RIFLE) criteria (Murugan & Kellum, 2011). Figure 1 illustrates the 
numerical values associated with diagnosing AKI using the RIFLE criteria. While the 
development of the RIFLE criteria was instrumental in providing a consistent standard to 
measure the degree of AKI, it was further modified by the Acute Kidney Injury Network 
(AKIN) in 2005 to include an important subset of patients who had decreased renal 
function more pronounced than physiological variation but not enough to meet RIFLE 
criteria as a result of early or mild AKI (Murugan & Kellum, 2011).  
 HA-AKI is generally seen in specific settings. Patients have a high incidence of 
developing HA-AKI if they also present with comorbid conditions such as diabetes 
mellitus, congestive heart failure, or have been admitted to the Intensive Care Unit (ICU), 
most commonly as a result of multiple organ failure. The development of end-stage renal 
disease (ESRD) is as high as 40% in patients who have had insulin-dependent diabetes 
mellitus (IDDM) for 20 years (“Complications of Diabetes Mellitus,” n.d.). A clinical 
epidemiologic study on the risk factors of HA-AKI showed that patients with diabetes 
were affected to a greater extent by volume depletion during an episode of AKI than 
patients without diabetes (Shusterman et al., 1987). The same study also showed that 
there is statistically significant evidence that congestive heart failure is a risk factor for 
developing AKI (Shusterman et al., 1987). While the development of AKI in hospitalized 
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patients is already frequent, HA-AKI is even higher for patients admitted to the ICU with 
reports ranging from 22-67% (Murugan & Kellum, 2011).  
 
Figure 1 RIFLE Criteria For Acute Kidney Injury. A patient moves from risk (class 
R) to failure (class F) as GFR and UO deteriorate. GFR = glomerular filtration rate. Screat 
= serum creatinine concentration. UO = urine output. Figure taken from (Bellomo, 
Kellum, & Ronco, 25).  
 
 
 
BACKGROUND 
 The development of Acute Kidney Injury has been classified into two different 
categories: Community-Acquired Acute Kidney Injury (CA-AKI) and Hospital-Acquired 
Acute Kidney Injury (HA-AKI). A patient is said to have CA-AKI if upon admission, the 
patient’s serum creatinine level is elevated enough to clinically classify as AKI under the 
RIFLE criteria (Schissler et al., 2013). Similarly, a patient is diagnosed with HA-AKI if 
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the patient presents with an increasing serum creatinine level twenty-four hours or more 
after being hospitalized (Schissler et al., 2013). A retrospective analysis of patient 
information at a Veterans Affairs hospital has shown that while different physiological 
causes may lead to CA-AKI versus HA-AKI, there is no significant difference in the 
severity of AKI between the two when comparing serum creatinine levels and using the 
RIFLE criteria to quantify the distribution of patients among the different categories 
(Schissler et al., 2013). Therefore, it is important to first understand how kidney injury 
occurs and what physiological changes result in the fluctuation of biomarker levels that 
are currently being used to diagnose and classify AKI. 
 
The Progression of AKI  
 The most common cause of AKI is Acute Tubular Necrosis (ATN), and this 
usually follows a form of ischemia or nephrotoxic injury to the renal tubules (Tolwani, 
2012). Table 1 lists out examples of different sources of nephrotoxic and ischemic injury. 
For patients that are already in the ICU, ATN can develop from a combination of factors 
including nephrotoxic medications, sepsis, and compromised renal perfusion (Schrier et 
al., 2004). The development of ischemic ATN can be categorized into four chronological 
phases: initiation, extension, maintenance, and recovery (Tolwani, 2012).  
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Table 1 Etiologies of Acute Tubular Necrosis. Acute Tubular Injury can arise from an 
array of different sources. The most common include nephrotoxic injury, ischemia, and 
sepsis. Table taken from (Palevsky, 2012). 
 
The initiation phase is set off by extended periods of renal ischemia and usually 
presents with injury directly to both the endothelial cells and the epithelial cells lining the 
renal tubules (Sharfuddin & Molitoris, 2011).  Once these cells have undergone physical 
injury, the Glomerular Filtration Rate (GFR) usually decreases (Tolwani, 2012). 
Although it is not completely understood how tubular injury results in the decreased 
function of the glomeruli, three major mechanisms have been determined to play a role in 
the observed decrease in renal function (Palevsky, 2012).  
1. Tubular obstruction – the renal tubule epithelial membrane ruptures following 
ischemia or nephrotoxic injury resulting in obstructions of the tubular lumen 
(Palevsky, 2012). 
2. Glomerular filtrate back leak – the glomerular basement membrane (GBM) can be 
compromised as a result of luminal obstruction and retrograde flow across the 
GBM (Palevsky, 2012). 
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3. Intrarenal vasoconstriction – although ATN is characterized by injury to the 
tubular epithelium, there is still a reactive vasoconstriction in the 
microvasculature that directly results in decreased glomerular perfusion and GFR 
(Palevsky, 2012).  
Injury to the kidney enters the extension phase as continued injury to the tubular 
epithelium and endothelium activate inflammatory mediators, which exponentially 
increase cellular injury (Tolwani, 2012). As with other organ failures, the progression of 
AKI is characterized by cytokine activation and subsequent systemic inflammation 
(Murugan & Kellum, 2011). This is because the injured cells release danger-associated 
molecules that carry on the inflammatory response to organs remote to the site of injury, 
leading to activated immune cells and the inflammation of these remote organs (Murugan 
& Kellum, 2011). The third phase, maintenance, typically lasts severl weeks, and during 
this time, the GFR re-stabilizes at a much lower level while the potential for other uremic 
complications increases (Tolwani, 2012). Physical complications include a decrease in 
urine output, and during this time, most patients rely on one form of renal replacement 
therapy, whether it be continuous hemofiltration or dialysis (Palevsky, 2012). During the 
fourth and final phase, recovery, the tubular epithelial cells undergo repair and 
regeneration with a subsequent and gradual improvement in GFR (Tolwani, 2012). 
Sometimes this is also called the diuretic phase because of the brisk increase in urinary 
output (Palevsky, 2012). Unfortunately, even if the GFR recovers to nearly normal levels, 
the residual injury to the renal tubules leads to an overall decrease in GFR compared to 
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baseline, a loss of the ability to acutely increase the GFR following certain stimuli, and 
other symptoms that may last for months or years (Palevsky, 2012).  
 
Traditional Biomarkers Used To Diagnose AKI 
 Since the renal system is responsible for maintaining physiologic homeostasis in 
the body, it is essential to assess overall kidney function, and GFR has become the 
indicator used by doctors in the clinical setting while caring for patients. Accurately 
measuring GFR is important because its measurement can help doctors to assess the 
severity of renal dysfunction or determine how far along kidney disease has progressed. 
However, it is not physically possible to measure GFR directly, so instead, it is calculated 
by measuring the renal clearance of filtration markers (Stevens & Levey, 2005). It is 
important that GFR is calculated using the renal clearance of a substance whose plasma 
concentration is stable, is non-reactive, and is filtered freely in the glomeruli while 
simultaneously not being metabolized, secreted, or reabsorbed (Stevens et al., 2006). An 
endogenous biomarker that fits all those ideal characteristics does not exist, but serum 
creatinine and serum urea have been used in the clinical setting to measure the level of 
renal function.  
 The best overall measurement of renal function is GFR. Factoring in age, gender, 
and body size, the normal value in young men is about 130 ml per minute per 1.73 m2, 
and the normal value in young women is about 120 ml per minute per 1.73 m2 (Stevens et 
al., 2006). GFR can be measured by calculating the plasma or urinary clearance of a 
marker with ideal characteristics such as inulin or also by using exogenous markers such 
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as iohexol, iothalamate, diethylene triamine pentaacetic acid, and 
ethylenediaminetetraacetic acid (Stevens et al., 2006). However, measuring the clearance 
of these exogenous markers can be expensive, complex, and difficult to do routinely in 
the clinic (Mohanram & Toto, 2005). In addition, studies have shown that there are 
variations in clearance measurements, with errors as high as 20 percent, when using these 
exogenous markers to calculate GFR whether procedures are done on the same day or 
different days, and these variations increase at higher absolute scale GFR measurements 
(Stevens et al., 2006). And although inulin meets the requirements that the marker to 
measure GFR should be freely filtered in the glomerus while not being secreted, 
reabsorbed, or metabolized, it needs to be infused intravenously, leading to its use mainly 
as a research tool and not in clinical practice (Perrone et al., 1992).  
 
Serum Creatinine 
 It has been widely interpreted over many years that serum creatinine 
concentration is a measure of GFR and that GFR is an overall indication of renal function 
in the clinical setting (Perrone et al., 1992). In fact, there have been many studies that 
support the reciprocal relationship GFR has with the serum creatinine level and the direct 
relationship GFR has to creatinine clearance (Stevens & Levey, 2005). However, 
creatinine is far from a perfect tool in measuring renal function through GFR. There are 
innate differences in the level of serum creatinine among different racial, ethnic, 
geographic, and age groups which is most probably attributed to the fact that muscle 
mass and dietary habits primarily determine how much creatinine is generated (Stevens et 
9 
al., 2006). Table 2 lists examples of the effect age, gender, race, body type, illness, and 
diet have on serum creatinine levels.  
Table 2 Factors That Affect The Generation of Creatinine. Variation in muscle mass 
predominantly accounts for differences in creatinine production. Caucasian race was used 
as a reference when comparing ethnic groups. Table taken from (Stevens et al., 2006). 
 
 Creatinine is derived from amino acids, has a molecular mass of 113 Daltons, and 
is freely filtered in the glomerulus (Stevens et al., 2006). However, if it is used as a 
marker for GFR, it is assumed that 2 criteria need to be met: 
1. Creatinine must be a perfect filtration marker (Perrone et al., 1992). 
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2. The metabolism of creatinine must be constant over time among different 
individuals while the renal extraction rate of creatinine equals the production rate 
(Perrone et al., 1992). 
From Table 2, it is already apparent creatinine production can vary greatly among 
different individuals. And while creatinine fulfills many of the requirements to be a 
perfect filtration marker, it does not meet them all (Perrone et al., 1992). Creatinine is not 
protein bound, is filtered freely, is not subject to renal metabolism, and is physiologically 
non-reactive (Perrone et al., 1992). However, since the proximal tubular cells in the 
nephron secrete creatinine while simultaneously being filtered freely by the glomerulus, 
the clearance of creatinine usually exceeds the actual GFR (Stevens et al., 2006). In fact, 
the proximal tubular secretion of creatinine can result in the creatinine clearance 
exceeding inulin clearance by up to 40 percent (Perrone et al., 1992). This overestimation 
of renal function based on a falsely high creatinine clearance can be potentially 
dangerous in the clinical setting. This is because a higher creatinine clearance based GFR 
calculation can inaccurately estimate the level of renal functionality and fail to identify 
the beginning of renal insufficiency and also result in incorrect medication dosages being 
prescribed to patients suffering from chronic kidney disease (CKD) (Levey et al., 1999). 
Nonetheless, creatinine clearance has been used as the standard for measuring GFR and 
overall renal function. In clinic, creatinine clearance can physically be computed by using 
timed 24-hour urine collections along with concurrent blood sampling (Stevens et al., 
2006). However, these timed collections are easily subjected to human error and are 
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cumbersome to those involved, so this type of measurement is no longer a recommended 
way to routinely estimate the level of renal function (Stevens et al., 2006).  
 
Equations To Estimate GFR 
 In order to account for the many variables affecting GFR measurements such as 
age, gender, ethnicity, and serum creatinine, estimating equations have been developed 
and used widely to overcome the limitations of using serum creatinine alone (Stevens et 
al., 2006). In fact, studies have shown that these equations based on the serum creatinine 
level in conjunction with other variables performed much better in correctly calculating 
GFR when compared to using serum creatinine levels alone (Coresh et al., 2002). Table 3 
lists out the 7 different GFR estimating equations that were compared in a 1999 study 
investigating the accuracy of GFR prediction from serum creatinine levels. The two most 
commonly used equations are the Cockroft-Gault formula and the MDRD study equation 
which are represented by equations 2 and 7 respectively in Table 3. The Cockcroft-Gault 
formula was created in 1973 while the MDRD study equation was created in 1999 
(Stevens et al., 2006).  
Although the Cockcroft-Gault equation was used widely in the past, it 
overestimated GFR because it did not take into account the tubular secretion of creatinine 
(Stevens et al., 2006). Because it did not take into account the adjustments needed for 
body-surface area, there needs to be additional measurements of height, calculation of 
body-surface area, and a re-calculation to 1.73 m2 in order to compare the Cockcroft-
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Gault equation to normal creatinine clearance values (“Frequently Asked Questions 
About GFR Estimates,” n.d.).  
Table 3 Equations Using Serum Creatinine Concentration to Predict Glomerular 
Filtration Rate. (ml/min per 1.73 m2) Alb = serum albumin concentration (g/dl); CCr = 
creatinine clearance (ml/min per 1.73 m2); Curea = urea clearance (ml/min per 1.73 m2); 
PCr = serum creatinine concentration (mg/dl); SUN = serum urea nitrogen concentration 
(mg/dl); UUN = urine urea nitrogen concentration (g/d); SCr = serum creatinine 
concentration (mg/100ml). Cockcroft-Gault formula is CCr = [(140-age)(wt kg)]/72!SCr 
(Cockcroft & Gault, 1976). Table taken from (Andrew S. Levey et al., 1999). 
 
Conversely, the MDRD study equation has already adjusted for body-surface area in 
calculating the GFR (Levey et al., 2000). Out of all 7 equations tested, the ones that used 
estimated or measured creatinine as a basis for GFR calculation tended to overestimate 
GFR (Levey et al., 1999). Even after correcting for these systematic errors in GFR 
overestimation, the MDRD study equation produced the least variation when comparing 
the predicted GFR with the measured GFR (Levey et al., 1999). In fact, the MDRD study 
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equation provides reasonably accurate GFR measurements for non-hospitalized patients 
who had been diagnosed with chronic kidney disease (Stevens et al., 2006). These 
equations provide another advantage in the clinical setting because it can be difficult to 
quantify and appreciate the degree and rate of change in GFR by only measuring changes 
in serum creatinine levels because of the reciprocal relationship between serum creatinine 
levels and GFR (Stevens et al., 2006). For example, if you take a 50-year-old Caucasian 
male: 
1. An increase in serum creatinine from 1.0 to 2.0 mg/dl (88.4 to 176.8 µmol/l) 
correlates to a GFR decrease of 46 ml/min per 1.73 m2 (Stevens et al., 2006). 
2. However, a further increase in serum creatinine from 2.0 to 3.0 mg/dl (265.2 
µmol/l) only correlates to a GFR decrease of 14 ml/min 1.73 m2 (Stevens et al., 
2006). 
Therefore, these equations provide the advantage of directly calculating for GFR instead 
of creating the need to extrapolate and interpret the magnitude of GFR change from 
reciprocal changes in serum creatinine levels. 
 
Limitations of Traditional Biomarkers 
 Although serum creatinine and blood urea nitrogen (BUN) have been used 
extensively in the past as biomarkers for kidney injury, their utility has limitations. As 
mentioned earlier, serum creatinine levels innately fluctuate among individuals based on 
age, body type, ethnicity, and other factors. Therefore, serum creatinine levels do not 
present great sensitivity or specificity in early detection of renal injury (Lattanzio & 
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Kopyt, 2009). Similarly, BUN levels are not sensitive or specific enough in diagnosing 
AKI because its levels are also affected by renal and non-renal factors alike, independent 
of both kidney injury or function (Urbschat et al., 2011). The production of these 
biomarkers does not necessarily differentiate between normal renal function and an active 
lesion that may indicate active kidney damage (Mori & Nakao, 2007). For example, urea 
nitrogen production is not constant because it can increase with a diet high in protein or 
with enhanced breakdown of tissue from a trauma, but it can also decrease with a diet 
low in protein or advanced liver disease, all without a change in GFR (Proulx et al., 
2005).  
Serum creatinine concentration has its own fluctuations with body characteristics, 
but it presents another challenge in being used to identify kidney injury because its levels 
may not change until kidney function has already decreased to an appreciable degree 
(Urbschat et al., 2011). This means that kidney injury has already occurred by the time 
serum creatinine levels are elevated. Another physiologic limitation of even greater 
importance is that because of the tubular secretion of creatinine, renal function is 
overestimated especially at lower GFR values (Urbschat et al., 2011). Lower GFR values 
already indicate more advanced renal injury, so an overestimation of kidney function at 
this stage could potentially amplify other health risks. For example, a study has shown 
that creatinine production as a whole was dramatically decreased in mice with sepsis, so 
this artificially low serum creatinine level overestimated renal function and made it an 
even poorer tool in evaluating renal damage (Doi et al., 2009).  
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There have been benefits in using equations to estimate GFR instead of only 
relying on serum creatinine measurements, but these equations also have their limitations 
because patients need to be stable or have a chronic kidney dysfunction in order for the 
equations to have any utility (Urbschat et al., 2011). It is difficult to use the GFR 
equations in acute cases such as AKI because GFR is already reduced significantly in a 
short time before serum creatinine has the opportunity to accumulate (Urbschat et al., 
2011). Nevertheless, the historical use of serum creatinine levels and BUN in conjunction 
with GFR estimation equations to identify renal injury has set a foundation for AKI 
diagnosis and treatment, and over the years, methods have been modified to create a 
standard in diagnostics that will help perpetuate further advancements in the field.  
 
 
Historical Classification of AKI 
 Before the 1800s, there were few references to AKI (Srisawat et al., 2010). 
However, even in the second century AD, the investigation of one man named Galen 
created the foundation for using anatomically accurate models to understand the 
functions of the human body (Eknoyan, 1989). By essentially laying down the 
groundwork for experimental physiology, Galen defined the differential diagnosis of 
ischuria, the suppression of urine output, using a physical examination to see if a patient 
presents with a distended bladder or not (Eknoyan, 1989). By the end of the 18th century, 
the famous pathologist and anatomist Batista Morgagni introduced, for the first time, 
terminology that defined ischuria based on kidney pathology (Eknoyan, 2002). These 
terms included ischuria renalis, ischuria ureterica, uschuria vesicalis, and ischuria 
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urethralis (Eknoyan, 2002). By the beginning of the 1900s, acute renal failure (ARF) was 
called acute Bright’s disease, and during this time, extensive microscopic and 
macroscopic pathological study in conjunction with major contributions by military 
medicine in the area of traumatic shock added to the development of study in this field 
(Srisawat et al., 2010). During World War II, there were cases of impaired function of the 
kidney following crush injuries, and an examination of the pathology of the kidney 
showed that there was pervasive damage to the renal tubules along with pigmented casts 
inside the tubules (Srisawat et al., 2010). Once these studies created the groundwork for 
future investigation into acute renal failure, the actual term “acute renal failure” was 
finally introduced in 1951 by Homer W. Smith in his textbook The Kidney. Structure and 
Function in Health and Disease (Srisawat et al., 2010). During the 1950s, three 
physicians by the names of William J. Kolff, John P. Merril, and George E. Schreiner 
greatly added to the knowledge on ARF by respectively making contributions like 
inventing the artificial kidney, creating the management and clinical course of ARF, and 
describing and encouraging the treatment of ARF (Srisawat et al., 2010). Figure 2 
provides a short timeline illustrating all these milestones. 
 
Figure 2 Timeline Illustrating Milestones in the History of AKI. Figure taken from 
(Srisawat et al., 2010). 
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Even with the advancements made throughout history in the study of kidney 
injury, one of the recent points of emphasis was developing a clear definition of AKI 
because realistically, a patient can neither be diagnosed nor cleared of AKI until there is a 
universally accepted set of criteria to follow (Ricci et al., 2007). The creation of this 
criteria was extremely important because even a relatively small impairment in kidney 
function needs to be considered as an independent mortality risk factor (Joannidis et al., 
2009). In fact, studies have shown that even a rise in serum creatinine of 0.5 mg/dl can 
increase the odds of death due to kidney injury by a factor of six (Chertow et al., 2005). 
Not only that, but even in instances of survival, a serum creatinine increase of 2.0 mg/dl 
was correlated with an increase of $34,000 in total hospital costs (Chertow et al., 2005).  
Nevertheless, before 2004, there were over 35 different definitions ARF in 
medical literature resulting in a lack of diagnostic criteria to follow (Srisawat et al., 
2010). This lack of uniformity has limited and impaired studies looking into the 
epidemiology and outcomes for critically ill patients (Chang et al., 2010). For example, 
studies measuring the rate of AKI in patients admitted for acute decompensated heart 
failure (ADHF) have ranged from 10 to 40% because of the varying definitions for AKI 
in the ADHF population, and other outcomes such as in-hospital death and readmission 
due to heart failure can vary wildly between studies (Roy et al., 2013). Conventionally, 
the term ARF was reserved for patients who required acute dialysis support and were 
usually admitted to the ICU, but because of the clinical importance of even small 
increases in serum creatinine, there was a need to classify the entire spectrum of kidney 
injury (Srisawat et al., 2010). Therefore, in 2004, the Acute Dialysis Quality Initiative 
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(ADQI) created a working definition and classification system for AKI that included the 
following features: 
1. Simplicity and clinical applicability across different healthcare centers 
(Bellomo et al., 2004). 
2. Specificity and sensitivity in various populations and relevance to 
questions in research (Bellomo et al., 2004). 
3. Evaluation of changes in creatinine levels from a measured baseline value 
(Bellomo et al., 2004). 
4. Creation of a classification system for acute on chronic renal disease 
(Bellomo et al., 2004). 
This new classification system should distinguish both between early or late cases and 
mild or severe cases, thereby effectively categorizing and detecting patients with mildly 
affected renal function and patients with severely affected renal function (Ricci et al., 
2007). 
 
RIFLE Criteria 
 In 2004, the ADQI group in conjunction with representatives from the American 
Society of Nephrology (ASN), the International Society of Nephrology (ISN), the 
National Kidney Foundation (NKF), and the European Society of Intensive Care 
Medicine (ESICM) proposed the terminology “acute kidney injury” to describe how 
acute renal dysfunction is actually composed of an entire spectrum of severity that 
usually follows an injury to the kidney affecting structural and functional changes in the 
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kidney (Ricci et al., 2007). They looked to standardize the definition of AKI in a way that 
was already done in two other syndromes common to the ICU: sepsis and Acute 
Respiratory Distress Syndrome (ARDS) (Srisawat et al., 2010). The study that this group 
conducted was focused on first creating a clear definition of ARF, but it also looked to 
form a foundation for future research by focusing on other things such as an evaluation of 
different animal models in ARF research and an assessment on the appropriate use of 
physiological and clinical end-points in testing new ARF treatments (Bellomo et al., 
2004). This group was able to successfully reach a consensus on a total of 47 questions 
integrating the intended points of emphasis by reviewing the evidence available 
concerning optimal practice in these areas (Bellomo et al., 2004).  
 First, a definition and classification system was developed for ARF because 
without a set of universally accepted criteria, ARF occurrence ranged from 1% to 25% in 
critically ill patients, and death ranged from 28% to 90% depending on which population 
was studied and what criteria was used to diagnose ARF (Bellomo et al., 2004). It was 
first determined to use measures of serum creatinine and urine output in determining the 
severity of ARF because these functions are unique to the kidney with values that are 
easily measured (Bellomo et al., 2004). Measures of BUN were excluded because it is not 
as specific a marker of renal function when compared to creatinine (Bellomo et al., 
2004). Figure 1 illustrates the numerical values associated with the severity scale for both 
the GFR criteria and the urine output criteria. The criteria that leads to the worst stage 
outcome is the one used in grading ARF (Bellomo et al., 2004). As Figure 1 shows, the 
acronym RIFLE refers to the Risk of renal dysfunction, Injury to the kidney, Failure of 
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kidney function, Loss of kidney function, and End-stage kidney disease (ESKD) 
(Bellomo et al., 2004). The first 3 categories are used to assess the severity of renal 
dysfunction while the latter 2 categories indicate clinical outcomes (Bellomo et al., 
2004). The 2 different clinical outcomes acknowledge that there is a difference in 
adaptations that must occur in ESKD that are not observed is persistent ARF (Bellomo et 
al., 2004). For example, while ESKD is defined by the required use of dialysis for greater 
than 3 months, persistent ARF is defined as the necessary use of renal replacement 
therapy (RRT) for greater than 4 weeks (Bellomo et al., 2004). The RIFLE criteria was 
created to have high sensitivity starting from the Risk assessment and move down to have 
high specificity at the ESKD level (Bellomo et al., 2004). 
 One hurdle this classification system faces is the need for a baseline measurement 
of renal function. This is because many patients are diagnosed with acute dysfunction in 
their kidneys without ever having a baseline measurement to use as a reference and make 
assessments (Bellomo et al., 2004). Therefore, it was determined to use the MDRD 
formula to create theoretical baseline serum creatinine values, assuming normal GFR, for 
patients differing in age, race, and gender (Bellomo et al., 2004). Table 4 gives examples 
for estimated baseline serum creatinine levels for a few different populations.  
 The original intention for creating the RIFLE classification was to create a 
standard definition and severity scale for AKI, but other studies have shown that the 
RIFLE criteria also holds some predictive value in the clinic (Ricci et al., 2007). For 
example, a systematic review was done to evaluate the ability the RIFLE criteria had in 
predicting mortality in patients from the ICU, inside the hospital but not in the ICU, after 
21 
cardiac surgery, and in the pediatric ward (Ricci et al., 2007). While these patients had 
not presented to the hospital suffering from AKI, there was an increasing related risk for 
death when the RIFLE criteria was used to classify these patients from Risk to Failure 
(Ricci et al., 2007). The one population where this trend did not hold was in patients who 
already required RRT, but it was suggested that this was probably because for those 
patients that are already severely ill, the RIFLE criteria is not able to discriminate 
between the Risk, Injury, and Failure classes (Ricci et al., 2007). 
Table 4 Estimated Baseline Serum Creatinine Levels Using the MDRD Formula. 
Estimated GFR = 75 ml/min per 1.73 m2 = 186 ! (serum creatinine [SCr]) – 1.154 ! (age) 
– 0.203 ! (0.742 if female) ! (1.210 if black) = exp(5.228 – 1.154 ! ln[SCr]) – 0.203 ! 
ln(age) – (0.299 if female) + (0.192 if black). Table taken from (Bellomo et al., 2004). 
 
 The RIFLE criteria made significant and necessary advancements in creating a 
standardized set of diagnostic measurements for AKI, but it still had limitations and room 
for improvement. One limitation was that while urine output is very specific and sensitive 
to the kidney, its variability due to external factors has led to its omission in many studies 
(Ricci et al., 2007). Some problems include: 
1. The use of diuretics can compromise the sensitivity and specificity of urine output 
for grading AKI (Ricci et al., 2007). 
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2. Urine output needs to be accurately assessed, but this is usually only possible with 
a urinary catheter making proper urine output measurement feasible in the ICU 
but less so in the wards (Ricci et al., 2007). 
3. The urine output criteria, being too sensitive and not specific enough, has not 
been proven to be well balanced with the serum creatinine criteria when defining 
the Risk, Injury, and Failure categories. This has led to patients diagnosed using 
the serum creatinine criteria being more severely ill in each category than patients 
diagnosed using the urine output criteria (Ricci et al., 2007). 
Another limitation of the RIFLE criteria is that a baseline serum creatinine level 
measurement is needed as a reference point (Ricci et al., 2007). Although the MDRD 
formula has provided theoretical baseline values for different populations, the values are 
inherently non-universal for all individuals, and the validity of these values has been 
questioned (Hoste & Kellum, 2006). Finally, the RIFLE criteria fails to account for the 
influence etiology of AKI has on the course of diagnosis and treatment, and it also does 
not consider the need for RRT as a factor in ranking the Risk, Injury, and Failure 
categories (Ricci et al., 2007). Therefore, subsequent modifications were necessary to 
account for some of these shortcomings.  
 
AKIN Modification to RIFLE Criteria 
 When the ADQI created the RIFLE criteria, they also established the Acute 
Kidney Injury Network (AKIN), which was comprised of experts from the leading 
kidney research societies, to work as a collaborative network and use their expertise to 
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facilitate international, interdisciplinary, and intersocietal collaboration in order to 
advance the field of AKI research (Mehta et al., 2007). When this group met for their first 
conference in 2005, they worked to create additional criteria in defining and classifying 
AKI. The focused on 6 concepts in creating this diagnostic criteria: 
1. The definition has to be broad enough to encompass and recognize deviations in 
clinical presentation across different age groups, geographic locations, and 
clinical situations (Mehta et al., 2007). 
2. Since serum creatinine levels and urine output can be influenced by other factors 
besides GFR, other biomarkers that are more sensitive and specific to kidney 
injury need to be the future of diagnosis and prognosis (Mehta et al., 2007). 
3. Small variations in serum creatinine levels can have adverse outcomes too, but 
current clinical practices usually attributes this to lab variations and does not give 
much attention to it (Mehta et al., 2007). 
4. It was observed that adverse outcomes occurred when small changes in serum 
creatinine presented within 24 to 48 hours. Therefore, a time constraint for 
diagnosis was placed at 48 hours in order to eliminate “non-acute” increases in 
serum creatinine that may change by 0.3 mg/dl over a longer period of time 
(Mehta et al., 2007). 
5. Further evaluation needs to be done for patients with CKD to see if the serum 
creatinine concentration elevation of 0.3 mg/dl is still applicable to them since 
AKI can often present superimposed with pre-existing CKD (Mehta et al., 2007). 
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6. Urine output criteria needs to be included because it can be used as a diagnostic 
measure for critically ill patients when renal dysfunction is present before there is 
enough time for serum creatinine levels to increase (Mehta et al., 2007).  
There was some dissent among a small subset of AKIN members who argued that a urine 
output reduction of 0.5 ml/kg per hour over 6 hours was not specific enough to diagnose 
AKI, and that the difficulty to accurately measure urine in non-ICU conditions in 
conjunction with the effect of diuretics on urine output made it a problematic measure for 
AKI (Mehta et al., 2007). Nevertheless, it was determined that even with the possible 
increase in false-positive results, it was still an improvement on the current state of 
diagnosis where AKI was under-recognized and many patients were identified in late 
stages of their illness (Mehta et al., 2007). Since the purpose of this diagnostic criteria 
was to increase the clinical awareness and diagnosis of AKI, even though some patients 
labeled with AKI may not actually have the condition, it allows the opportunity for 
prevention and procedures to prevent further kidney damage (Mehta et al., 2007). Table 5 
shows the changes proposed by the AKIN criteria in both diagnostic measurements and 
naming of stages. 
 The AKIN criteria made some changes to the RIFLE criteria but also retained 
many of its recommendations. Since the importance of small changes in serum creatinine 
levels had been emphasized, the AKIN criteria included that modification in Stage 1. 
Even though AKI is diagnosed over a period of 48 hours, progression through the stages 
occurs over a longer time period, and the AKIN criteria maintained the time frame of one 
week that was proposed by the ADQI group (Mehta et al., 2007). While the RIFLE 
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criteria included the therapy required in treating AKI to define the Loss and ESKD 
categories, the AKIN group consciously did not include them because they were viewed 
as outcomes of AKI as opposed to stages of AKI (Mehta et al., 2007). While Stage 1 in 
the AKIN criteria was made analogous to the Risk category in the RIFLE criteria, Stage 2 
and Stage 3 were equated to the Injury and Failure categories respectively (Mehta et al., 
2007). Finally, all patients requiring the administration of RRT were automatically placed 
in Stage 3 of the AKIN criteria because the variability in commencing RRT in different 
populations and countries made it difficult to use it as a staging criteria between levels 
(Mehta et al., 2007). 
Table 5 Stages of Acute Kidney Injury As Defined by the RIFLE and AKIN 
Criteria. Table taken from (Palevsky, 2012). 
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Comparing RIFLE and AKIN Criteria 
 One of the main goals of the AKIN criteria was to increase the sensitivity of AKI 
detection by including the diagnostic measurement of an increase in serum creatinine of 
0.3 mg/dl or more within a 48-hour window. This new addition succeeded in its intended 
purpose while still maintaining some of the original benefits of the RIFLE criteria. There 
have been conflicting results where some studies showed that the AKIN criteria may not 
actually improve upon the RIFLE criteria’s sensitivity or predictive ability while other 
studies showed that the AKIN criteria showed superior sensitivity in detecting AKI but 
was inferior in its ability to predict outcomes in critically ill patients (Chang et al., 2010). 
Nevertheless, a study by Chang et al. showed that the AKIN criteria identified 7.9% more 
AKI patients than the RIFLE criteria (Chang et al., 2010). In addition, the AKIN criteria 
maintained the patient predictive ability as the mortality rates all increased when moving 
from Stage 1 to Stage 2 to Stage 3 as had been observed when moving from Risk to 
Injury to Failure in the RIFLE criteria (Chang et al., 2010). Even in a study specific to 
patients undergoing cardiac surgery, the AKIN criteria diagnosed significantly more 
patients with AKI when compared to the RIFLE criteria (Englberger et al., 2011).  
However, this is not always the case. Table 6 shows the distribution of critically 
ill patients classified in the different categories of both the RIFLE and AKIN criteria. As 
shown in the table, 14,356 patients were classified into different stages of AKI severity 
using these 2 classification systems. The horizontal rows define the AKIN stages while 
the vertical columns define the RIFLE stages. The boxes highlighted in yellow that make 
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the horizontal line across the table indicate the subpopulation of patients that were 
categorized to the analogous stages in both the RIFLE and AKIN staging levels. By 
adding those numbers up, we can see that 82.7% of patients were staged in consensus 
between these two classification systems.  
Table 6 Distribution of Critically Ill Patients Classified by the RIFLE and AKIN 
Criteria. A total of 14,356 patients were cross-classified using the RIFLE and AKIN 
criteria. The boxes highlighted in yellow represent the subpopulation of patients that were 
categorized to the same stage using the two classification systems. The bracketed 
percentages represent the mortality rate of each group. Table taken from (Joannidis et al., 
2009). 
 
Looking deeper into the table shows that the AKIN criteria does not necessarily show an 
increase in sensitivity when compared to the RIFLE criteria. By adding up the Risk, 
Injury, and Failure totals in the non-AKI AKIN row, it is obvious that 1,504 patients that 
were classified as non-AKI using the AKIN criteria were subsequently classified as AKI 
under the RIFLE criteria, with roughly half of them falling in the Risk category 
(Joannidis et al., 2009). Conversely when adding up the Stage 1, Stage 2, and Stage 3 
totals in the non-AKI RIFLE column, 504 patients that were classified as non-AKI using 
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the RIFLE criteria were subsequently classified as AKI under the AKIN criteria, with 
nearly all of them falling in Stage 1 (Joannidis et al., 2009). This shows that using either 
criteria alone leaves room for missing diagnoses in patients, and depending on the patient 
population, either the RIFLE or the AKIN criteria may be more sensitive. Figure 3 
illustrates how this may be the case. 
 
Figure 3 Illustrative Cases on the Diagnosis of AKI Using the RIFLE and AKIN 
Staging Criteria. All patients have a baseline serum creatinine level of 1.0 mg/dl. Figure 
taken from (Srisawat et al., 2010). 
 
Figure 3 follows the serum creatinine concentration of 5 hypothetical patients for seven 
days following admission to the hospital, all with a baseline serum creatinine level of 1.0 
mg/dl.  
1. Case 1 shows how the AKIN modifications can allow for earlier detection of AKI 
(Srisawat et al., 2010). Using the AKIN criteria, patient 1 could be diagnosed with 
AKI as early as day 3 since a serum creatinine level of 1.3 mg/dl meets the Stage 
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1 requirement of a 0.3 mg/dl increase over baseline within a 48 hour period 
(Srisawat et al., 2010). Conversely, the RIFLE criteria would not have diagnosed 
AKI in the Risk category until day 5 because a 150% baseline measurement of 
serum creatinine would not be reached until it hit the value 1.5 mg/dl (Srisawat et 
al., 2010). Moreover, if the patient’s serum creatinine level had peaked at 1.4 
mg/dl, the RIFLE criteria would have never even classified this as a case of AKI, 
thus potentially missing the progression of a deadly disease (Srisawat et al., 
2010). The severity of AKI reaches a maximum on day 6 at Stage 2 using the 
AKIN criteria and Injury using the RIFLE criteria.  
2. Case 2 shows an instance where AKI is diagnosed on the same day regardless of 
which classification system is used (Srisawat et al., 2010). The RIFLE criteria 
cannot diagnose AKI until day 5 because the serum creatinine does not reach 1.5 
mg/dl until then. Interestingly, this is a case where the AKIN criteria of an 
increase in serum creatinine of 0.3 mg/dl within a 48 hour period is not helpful in 
early diagnosis. Because of this requirement, AKI cannot be diagnosed using the 
AKIN criteria until day 5 as well because the serum creatinine increase is not 
acute enough from days 1-3 to classify as AKI. It is only when the serum 
creatinine concentration increases from 1.1 mg/dl on day 3 to 1.5 mg/dl on day 5 
that the AKIN criteria for Stage 1 is met.  
3. Case 3 shows how using the AKIN criteria alone could miss a case of AKI 
altogether. By applying the 48-hour time window rule alone, it is not possible to 
diagnose AKI because the serum creatinine concentration never rises 0.3 mg/dl 
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within that short a period of time (Srisawat et al., 2010). However, by also 
including the 150% baseline measurement of serum creatinine criteria, Stage 1 
and the Risk category are both diagnosed on day 6.  
4. Case 4 shows how the AKIN modification in using RRT treatment to 
automatically categorize to Stage 3 severity of AKI is utilized regardless of serum 
creatinine concentrations (Srisawat et al., 2010). Once again, the AKIN criteria 
diagnoses AKI on day 3 with an increase in serum creatinine of 0.3 mg/dl within 
48 hours, and the RIFLE criteria diagnoses AKI on day 5 once the serum 
creatinine concentration reaches 150% of the baseline measurement. However, 
the AKIN criteria will automatically place this patient in Stage 3 because RRT is 
started on day 6. 
5. Case 5 shows an instance of CA-AKI where the peak serum creatinine 
concentration is reached at or before admission into the hospital (Srisawat et al., 
2010). In this case, the patient can be diagnosed with AKI if the baseline of 1.0 
mg/dl is known or can be estimated using the MDRD equation (Srisawat et al., 
2010). However, even without knowing the baseline value or using the estimating 
equation, the stable serum creatinine measurement of 1.0 mg/dl on day 6 and 7 
confirm that this was, in fact, a case of AKI (Srisawat et al., 2010).  
As discussed, there have been significant advancements made in the recognition and 
classification of AKI in recent history. Current methods of measuring renal function 
using serum creatinine measurements and urine output have been good tools, but they 
have inherent limitations in detecting early kidney injury and creating a course of 
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treatment based on the etiology of kidney injury. The RIFLE criteria has set the 
foundation for future kidney research by creating a universal definition and staging 
system that was further modified to increase sensitivity by the AKIN criteria. Now, the 
next step is to find even more specific and sensitive biomarkers that can help detect AKI 
sooner, thus improving the prognosis, and apply these new tools to create beneficial 
modifications to the existing RIFLE and AKIN criteria. 
 
OBJECTIVES 
 The objective of this study is to investigate ways in which to build upon the 
RIFLE criteria and AKIN criteria and propose modifications that can be made and tested 
in future studies. These modifications will focus on increasing the sensitivity of AKI 
detection, increasing the ability to discover renal injury earlier, and finally helping to 
create a better prognosis for AKI patients by developing more specific and personalized 
treatments. Current methods of kidney injury detection focus on the physiological effects 
that come after kidney injury has already led to a decrease in organ function, but a better 
diagnostic approach would be to find a way to detect structural and function damage to 
the kidney before the secondary effects take place. This opens up a discussion on the new 
novel biomarkers that are presently being researched as signs of renal cell injury to 
conclude whether the RIFLE criteria should be modified further using these new 
biomarkers to allow earlier detection of AKI and hopefully lead to a better overall 
prognosis. 
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 Change in serum creatinine concentrations is a common measure of AKI 
development, but the concentration of these new biomarkers seem to change earlier than 
that of creatinine. Cystatin C concentration has been shown to measure changes in 
glomerular filtration rate, whereas kidney injury molecule-1 and neutrophil gelatinase-
associated lipocalin concentration have been shown to be related to tubular stress or 
injury. The hope is that these new biomarkers can be utilized to provide earlier 
indications of AKI and integrated into the RIFLE criteria, thereby resulting in better 
prognoses for at risk patients. 
 
PRESENTATION OF PUBLISHED RESULTS 
 As with many systemic diseases, a key factor in the treatment of AKI is early 
detection. However, the current standard of using serum creatinine concentration and 
urine output to measure renal function does not allow for this early detection because in 
some cases the damage to renal tubules may not be sufficient enough to create an 
appreciable change in serum creatinine (Han et al., 2007). In cases of more severe 
damage to the renal tubules, there is a time delay between the moment of injury and a 
measurable increase in serum creatinine (Han et al., 2007). Early detection is important 
for purposes of quick treatment, but it is also important because the lowest level of 
severity in the RIFLE and AKIN criteria presents the potential of reversibility in the 
physical and functional damages to the kidney (Srisawat et al., 2010). Therefore, in 
recent years, novel biomarkers that present with changes closer to the time of renal injury 
have been researched with the hope that they will help with earlier detection of kidney 
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injury as well as help elucidate the location of the intrarenal injury, differentiating among 
the proximal tubule, distal tubule, intersitium, and vasculature (Urbschat et al., 2011). A 
combination of early diagnosis and specific knowledge of the location of the injury can 
result in more personalized treatment and the potential for a better outcome for the 
patient. 
 The preclinical assessment of nephrotoxicity has been greatly advanced by the use 
of urinary biomarkers in detecting AKI in its early stages (Haase & Mertens, 2010). This 
is because this knowledge will help to assess and predict kidney injury through 
preclinical testing before overwhelming nephrotoxicity and loss of renal function become 
apparent (Haase & Mertens, 2010). The field of AKI is not the first to look for unique 
biomarkers as signs of injury to an organ. In fact, in the field of cardiovascular disease, 
serum troponin levels have been used to accurately diagnose and assess myocardial 
infarctions (Adiyanti & Loho, 2012). When a patient suffers from angina pectoris, the 
damaged myosin in the cardiac tissue releases troponin, so monitoring serum troponin 
levels can help to directly identify acute myocardial injury (Adiyanti & Loho, 2012). 
There is a hopeful outlook that the same can be done in the field of AKI. 
 The body’s natural inflammatory response plays a major role in the initiation and 
progression of AKI irrespective of whether the injury results as a side effect of surgery or 
the patient is admitted to the ICU for a different condition (Mårtensson et al., 2012). In 
fact, AKI has in part been defined by the local and system inflammatory response 
following renal insult where many of the cytokines affect the kidney and other distant 
organs mediated by the systemic release of leukocytes from the kidneys and renal tubular 
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cells (Bihorac et al., 2013). Figure 4 illustrates the inflammatory mechanisms that lead to 
AKI and subsequent repair of the renal cells.  
 
Figure 4 Pathophysiological Mechanisms of AKI and Repair. The number of adhesion 
molecules on the surface of peritubular capillary endothelial cells increases which helps 
neutrophils to migrate into the interstitium and tubular lumen. Then inflammatory 
mediators, inflammatory mediators, and reactive oxygen species damage the tubular cells 
leading to the sloughing off of the brush border, improper location of Na+/K+ ATPase, 
and the beginning of apoptosis and necrosis. In the case of sever injury, parts of the 
basement membrane is left denuded as cells are desquamated. The pathophysiological 
changes worsen as even more inflammatory and vasoactive substances are released from 
the damaged tubular cells. If the renal cells are able to recover, viable cells differentiate 
to cover up the sections of bare basement membrane and begin to restore functionality in 
the nephron. AC = apoptotic cell, DC = differentiating cell, NC = necrotic cell. Figure 
taken from (Mårtensson et al., 2012).  
 
Ischemia, bacterial endotoxins, and nephrotoxins are some examples of triggers of AKI 
that lead to the release of inflammatory mediators from the endothelial cells of the 
capillaries and the tubular cells that make up the kidney (Mårtensson et al., 2012). These 
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cytokines and chemokines trigger the migration of neutrophils and other leukocytes to the 
inflammation site and facilitate the transfer across the interstitium to the injured tubular 
cells (Mårtensson et al., 2012). Even more leukocytes pass through the interstitium as the 
endothelial inflammatory response increases permeability across these barriers 
(Mårtensson et al., 2012). Once the leukocytes reach the tubular lumen, they release other 
pro-inflammatory cytokines that propagate tubular injury and eventually lead to the 
desquamation of cells, necrosis, and apoptosis (Mårtensson et al., 2012). Therefore, being 
able to track the levels of these kidney inflammation biomarkers can lead to early 
detection of tubular injury. 
 
Novel Biomarkers 
 The following have been suggested as properties an ideal biomarker would have 
in early detection of AKI: 
1. The biomarker must come from the damaged cells and be specific to the organ 
experiencing the injury (Mårtensson et al., 2012). 
2. As the extent of damage increases, the concentration of the biomarker must 
increase proportionally as well (Mårtensson et al., 2012). 
3. The temporal release of the biomarker must be close to the time of organ injury as 
this timing would help detect when the damage is still potentially reversible 
(Mårtensson et al., 2012).  
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4. Once the acute injury episode has subsided, the concentration of the biomarker 
should also decrease quickly in order for it to be used as a therapeutic monitoring 
tool (Mårtensson et al., 2012). 
5. The biomarker should be able to be measured rapidly and reliably (Mårtensson et 
al., 2012). 
Table 7 lists many different biomarkers that are currently being investigated, but this 
paper will focus on the properties and potential of three novel biomarkers that have 
recently shown promise in fulfilling these qualities: cystatin C, kidney injury molecule-1 
(KIM-1), and neutrophil gelatinase associated lipocalin (NGAL). 
Table 7 Novel Biomarkers for AKI Detection and Their Methods of Measurement. 
Table taken from (Adiyanti & Loho, 2012). 
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Cystatin C 
 Plasma cystatin C, a protease inhibitor, is known to be a good measure of kidney 
function because it is a more robust endogenous marker of GFR when compared to 
creatinine (Mårtensson et al., 2012). In addition to being constantly produced by all 
nucleated cells, this is the case for many reasons (Adiyanti & Loho, 2012): 
1. The production of cystatin C is relatively constant, and it is released into the 
plasma (Zhang et al., 2011). 
2. >99% of cystatin C is freely filtered by the glomeruli (Zhang et al., 2011). 
3. Cystatin C is not significantly bound to any proteins (Zhang et al., 2011). 
4. Cystatin C is not placed back into systemic circulation after being filtered because 
it is almost completely reabsorbed and catabolized in the renal tubules (Song et 
al., 2009).  
AKI was shown to be diagnosed one or two stages earlier based on the RIFLE criteria 
when measuring serum cystatin C levels as opposed to serum creatinine levels because 
cystatin C increases at a greater rate when exposed to contrast media (Adiyanti & Loho, 
2012). A study that compared the increase of cystatin C, serum creatinine, and BUN 
levels as a percentage of their baseline values in mouse models showed that cystatin C 
levels exhibited a significantly sharper and earlier increase in mice that had undergone 
bilateral nephrectomy (Song et al., 2009). 2 hours after the bilateral nephrectomy 
procedure, both the serum creatinine and BUN levels had increased similarly to around 
50% above their baseline values (Song et al., 2009). However, cystatin C levels had 
already increased to almost 300% over its baseline value (Song et al., 2009). Likewise, 
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after 12 hours, cystatin C levels had increased over 700% above its baseline value while 
serum creatinine and BUN had only increased 200%-300% above their baseline values 
(Song et al., 2009). After 24 hrs, cystatin C levels had reached nearly 1000% its baseline 
value while serum creatinine and BUN roughly maintained the 200%-300% increase it 
had already present with at the 12 hour mark (Song et al., 2009). Therefore, cystatin C 
has shown promise in its ability to detect renal damage significantly earlier than serum 
creatinine or BUN (Song et al., 2009). In fact, a study that investigated cystatin C’s 
ability to predict AKI concluded that cystatin C presented with its best diagnostic 
accuracy as early as 10 hours after admission into a hospital (Zhang et al., 2011). 
 However, just as serum creatinine had limitations due to external factors affecting 
creatinine production in different individuals, cystatin C is also influenced by factors not 
related to renal function (Knight et al., 2004). Cystatin C levels were observed to be 
affected by age, gender, race, presence of diabetes, white blood cell count, serum 
albumin, and C-reactive protein (Stevens et al., 2008). Therefore, it was proposed that the 
best way to estimate GFR may be to use a combination of serum creatinine and serum 
cystatin levels with the hope that this would minimize the effect extrarenal physiological 
processes have on these biomarker levels (Stevens et al., 2008). 
 
KIM-1 
 While cystatin C is seen as a marker of kidney function, KIM-1 is seen as a 
marker of kidney injury (Mårtensson et al., 2012). Studies have shown that when urinary 
KIM-1 levels were used to predict histopathological changes in the renal tubules, it 
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significantly outperformed the predictive abilities of serum creatinine and BUN 
(Mårtensson et al., 2012). KIM-1 is a type I cell membrane glycoprotein that is composed 
of a immunoglobulin-like domain uniquely made up of six cysteine residues (Vaidya et 
al., 2010). While the KIM-1 gene and associated protein are not expressed in the normal 
kidney, mice models have shown that gene expression and mRNA for KIM-1 increase 
more than any other known gene 24-48 hours after ischemia (Adiyanti & Loho, 2012). 
Epithelial cells express phosphatidylserine on their surface after undergoing apoptosis, 
and KIM-1 is used as a phosphatidylserine receptor on phagocytes, signaling them to 
dispose of the dead cells (Adiyanti & Loho, 2012). KIM-1 proteins are highly localized 
on the proximal tubular apical membrane in the region that was most affected by the 
injury (Vaidya et al., 2010). The ectoderm region of the KIM-1 protein is shed from the 
epithelial cells of the proximal tubule after the injury, and they are eventually excreted in 
the urine (Vaidya et al., 2010). Therefore, KIM-1 has shown great promise in mice 
models in serving as an early diagnostic indicator for kidney injury (Vaidya et al., 2010).  
 A study by Vaidya et al. has concluded that the ability of KIM-1 to indicate 
kidney injury makes it useful as a marker of nephrotoxicity, which means it can help in 
preventing organ damage during clinical drug development while simultaneously helping 
to monitor post-market nephrotoxicity as a side affect of the drug (Vaidya et al., 2010). 
N-acetyl-"-glucosaminidase (NAG) is a proximal tubular lysosomal enzyme that has also 
been shown to increase in urine concentration after exposure to nephrotoxic drugs 
(Adiyanti & Loho, 2012). Therefore, an increase in NAG can also indicates some form of 
tubular injury (Mårtensson et al., 2012). However, after being exposed to nephrotoxicants 
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and hepatotoxicants, urinary KIM-1 measurements still performed better than serum 
creatinine, BUN, and NAG in early detection of kidney injury with high specificity and 
sensitivity (Vaidya et al., 2010). However, because KIM-1 is an indication of cell death, 
it is important to evaluate how specific its presence is to renal cell death as opposed to 
cell death in other parts of the body. Interestingly enough, the KIM-1 levels in control 
groups and those exposed to hepatotoxic and cardiotoxic chemicals were similar (Vaidya 
et al., 2010). The fact that urinary KIM-1 level changes were unremarkable in cases of 
hepatotoxicity and cardiotoxicity in rat models shows that KIM-1 shows high specificity 
for kidney damage (Vaidya et al., 2010). 
 Ischemia and reperfusion injuries in rat models also showed that KIM-1 has an 
advantage over serum creatinine, BUN, and NAG. When looking at the histological 
changes following ischemia and reperfusion injury, there was low grade damage at 3-6 
hours, and after 9 hours, there was evidence of single cell necrosis, dilation of the 
tubules, and the sloughing off of dead cells (Vaidya et al., 2010). At 12-24 hours, 
histological slices showed that there was substantial necrosis in the proximal tubule with 
associated inflammation (Vaidya et al., 2010). There were only small transient increases 
in serum creatinine, BUN, and NAG between 3-9 hours, and statistically significant 
increases occurred much later: serum creatinine increased ~2.4 fold at 18 hours, BUN 
increased ~2.1 fold at 18 hours, and NAG increased ~5.5 fold at 12 hours (Vaidya et al., 
2010). Conversely, KIM-1 levels already showed up to ~6 fold increases at 3-6 hours, 
peaked at 24 hours with a ~700 fold increase, and leveled off at ~70 fold increase up to 
120 hours after reperfusion (Vaidya et al., 2010). 
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NGAL 
 As was the case with KIM-1, NGAL is also loosely categorized as a marker of 
kidney injury (Mårtensson et al., 2012). NGAL is a protein that is located in the 
secondary granules of neutrophils, and the secondary granules are released into the 
bloodstream in response to both bacterial and viral infections (Mårtensson et al., 2012). 
NGAL is normally expressed only in low amounts in different human tissues, but once 
there is some type of injury to epithelial cells like those in the kidney, the NGAL level 
rises significantly (Adiyanti & Loho, 2012). NGAL is filtered in the glomerulus and 
reabsorbed in the proximal tubules, so NGAL is detected in the urine either when there is 
damage to the proximal tubules to disrupt reabsorption or when there is an increase in 
NGAL synthesis (Adiyanti & Loho, 2012). It has been documented that NGAL mRNA 
expression can be increased up to 1000 fold in the ascending loop of the loop of Henle 
and the collecting ducts (Adiyanti & Loho, 2012). 
 One of the important roles NGAL has is helping to transport iron from cell to cell 
(Mårtensson et al., 2012). NGAL binds to siderophores, small iron-binding molecules, 
and its delivery of iron to the renal tubule cells induces the differentiation of progenitor 
cells into the epithelial cells of the renal tubules, thus helping in the injury-repair process 
(Mårtensson et al., 2012). Bacteria also produce siderophores in order to get the iron 
necessary for growth in surrounding tissues, so NGAL blocks the supply of iron to 
bacteria by binding to siderophores and may have a secondary effect as a bacteriostatic 
agent (Mårtensson et al., 2012). 
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 A characteristic that would be extremely beneficial in any new biomarker for AKI 
would be the ability to differentiate between the type of kidney injury, and NGAL has 
shown some promise in discriminating between pre-renal and intrinsic AKI (Mehta, 
2011). Although this area of study is still new, clinicians found that after reviewing 
clinical data, patients who presented with a concentration of NGAL less than 47 µg/l 
were identified as having pre-renal AKI, and patients who presented with a concentration 
of NGAL greater than 104 µg/l were identified as having intrinsic AKI (Mehta, 2011). 
This is important because the type of kidney injury can have an effect on the efficacy and 
course of treatment. This use of NGAL is analogous to the use of N-terminal brain 
natriuretic peptide (BNP) to discriminate between heart failure and other cause of 
pulmonary congestion (Mehta, 2011). However, further research needs to be conducted to 
use NGAL effectively in this way. 
 NGAL has been shown to detect AKI 36-48 hours earlier than serum creatinine, 
but that does not mean that AKI diagnosis cannot be improved by using beneficial 
aspects of both physiological measurements (McCullough et al., 2011). Studies showed 
that if only serum creatinine were used to diagnose AKI, up to 41% of patients with AKI 
would have been missed (McCullough et al., 2011). However, if patients present with 
elevated levels of both serum creatinine and urinary NGAL, they stayed in the ICU and 
hospital twice as long, required more dialysis, and experienced mortality three times 
higher than patients negative for both biomarkers (McCullough et al., 2011). A 
combination of these 2 measurements can also help to identify subgroups within the AKI 
patient population. For example, patients who were negative for NGAL but positive for 
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serum creatinine were likely to suffer from pre-renal azotemia or malfunctioning tubulo-
glomerular feedback without actually experiencing any acute tubular necrosis 
(McCullough et al., 2011). Conversely, patients who were positive for NGAL but 
negative for serum creatinine could indicate the presence of iron-dependant oxidative 
stress before any decrease in organ function is measureable (McCullough et al., 2011). 
 
DISCUSSION AND CONCLUSION 
 An investigation into the properties of cystatin C, KIM-1, and NGAL has shown 
that each of these new biomarkers provide a noticeable advantage in early detection of 
AKI over the traditional methods of tracking serum creatinine concentration and urine 
output. It is important to continue to make progress in the detection and treatment of AKI 
because it is becoming clearer that AKI should no longer just be considered in 
determining the severity of injury in critically ill patients (Bihorac et al., 2013). Injury to 
the kidney can have secondary effects in other organs like the lungs through the release 
of inflammatory mediators and leukocytes from the renal tubular cells (Bihorac et al., 
2013). Even with the advantages each new biomarker provides, a single biomarker by 
itself probably will not be adequate in providing all the necessary information such as the 
site of injury and projected course of treatment (Adiyanti & Loho, 2012). Therefore, there 
needs to be further research to see if a combination or panel of biomarkers can be used to 
provide the entire spectrum of information to effectively diagnose and treat AKI (Han et 
al., 2007). Figure 5 gives an illustration as to how new biomarker measurements could be 
incorporated into the already established RIFLE criteria. The important thing to notice is 
44 
that changes to multiple different markers of injury need to be used to balance out the 
shortcomings and innate biases that may be present from any single biomarker on its 
own. 
Figure 5 Theoretical Classification for the Next Generation in AKI Diagnosis. This 
new classification system could retain the function criteria provided by the current RIFLE 
criteria. A set of damage criteria could be added to measure the structural changes 
occurring in the renal tubules as markers for cell injury are monitored. Figure taken from 
(Murugan & Kellum, 2011). 
 
 As discussed, an ideal biomarker should be composed of certain characteristics. 
Cystatin C, KIM-1, and NGAL fulfill some of these requirements while leaving a void in 
others, and this opens up the possibility for future research in this field. First, it was 
suggested that the biomarker come from the cells that were damaged and be specific to 
the organ that was damaged (Mårtensson et al., 2012). Since cystatin C is produced by all 
nucleated cells, injury to the renal epithelial cells will be released. However, cystatin C 
has the limitation of being influenced by factors outside of renal functioning such as age, 
gender, and ethnicity. That is where a biomarker panel including measurements of KIM-1 
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and NGAL can be beneficial. Even though KIM-1 and NGAL are released by cells 
mounting an inflammatory response, they are closely associated enough with the actual 
site of injury to be applicable. Also, KIM-1 release has been shown to be very specific to 
kidney injury as opposed to injuries to other organs, so it can be used confirm damage to 
renal parenchyma cells as opposed to those of the liver or heart. Secondly, it was 
suggested that the concentration of the biomarker should increase proportionally as the 
extend of damage increases (Mårtensson et al., 2012). Studies have not investigated what 
level of increase in cystatin C, KIM-1, and NGAL is proportional to a certain level of 
renal injury, but each biomarker was shown to increase to a much higher degree than 
current measures of serum creatinine. In the cases of cystatin C and KIM-1, their levels 
increased 10-100 times the baseline measurement while serum creatinine and other 
traditional measurements maxed out at around 3-5 times the baseline measurement. 
Increases in serum creatinine also seems to plateau off earlier than these new biomarkers, 
so it would be interesting to investigate which biomarkers stop increasing while physical 
renal injury continues and which biomarkers increase throughout the entirety of the 
event. Thirdly, it was suggested that the biomarker be released as soon as possible after 
the moment of injury in order to diagnose AKI early when the damage is potentially 
reversible (Mårtensson et al., 2012). Studies showed that NGAL was able to detect AKI 
up to 48 hours earlier than serum creatinine, and both cystatin C and KIM-1 not only 
reached higher levels but also reached those levels at a much higher rate that serum 
creatinine. While there was no measurement as to how close to the time of injury these 
biomarkers were released, it is evident that they are detectable much earlier than 
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traditional methods. Finally, it was suggested that the biomarker levels decrease quickly 
after the acute injury has subsided as this can help in monitoring the patient 
therapeutically (Mårtensson et al., 2012). There has not been much research in this area, 
so the timing of biomarker level decrease can be a future area of study.  
 Knowing the properties of cystatin C, KIM-1, and NGAL provides a great 
platform for innovation in AKI diagnosis and treatment, but only have documentation 
that these biomarker levels increase quicker and to a much higher value than current 
measurements of serum creatinine is not sufficient. There needs to be further research 
into discovering what the cutoff values need to be for new biomarkers to be effective 
predictors of AKI (Zhang et al., 2011). There is some data that suggests that patients with 
a serum cystatin C level of less than 0.8 mg/l are less likely to develop AKI after some 
form of renal injury and that patients with a level greater than 2.04 mg/l have an 
increased risk of subsequently developing AKI (Zhang et al., 2011). However, these 
types of proposals need to be repeated across different clinical settings and a set of 
standardized values need to be agreed upon for all new biomarkers before they can 
provide universal benefit in the clinic. Moreover, even when testing these biomarkers, 
there needs to be caution in using creatinine as the “gold standard” to see their potential 
as injury markers (Mårtensson et al., 2012). Serum creatinine has been the standard for a 
long time, but because of its inherent limitations, it may be more effective to use less 
variable markers of kidney function like inulin in the controlled laboratory setting. 
Finally, many of the studies already conducted have evaluated the predictive properties of 
these biomarkers once the injury has already occurred. However, to truly study the ability 
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of these biomarkers to predict AKI, a more appropriate model would be a prospective 
case-controlled study (Mårtensson et al., 2012). Admittedly, this would be difficult to do 
in the ICU as most patients already present with AKI, but ideally, this study model would 
help estimate the predictive capabilities of these biomarkers even further. 
 The diagnosis and classification of AKI has come a long way in the last decade. 
Once a universal definition and set of criteria was set, the road for future research was 
laid out. Even with these advances, the incidence of mortality once AKI is sustained is 
undesirably high. The consensus has been that this is because physical injury cannot be 
detected early enough, and the window of reversible injury is usually missed. That is a 
direct result of using a secondary marker such as creatinine to measure the functional 
changes after physical damage has occurred. Therefore, these new biomarkers have great 
potential to improve detection and prognosis of AKI as the change in their levels is closer 
to the time of injury on the spectrum of measuring the physical and functional. Because 
the kidney plays a vital role in maintaining homeostasis in the entire body, advances in 
the field of AKI will have a positive impact on the outcome of patients in many fields 
other than its own. 
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